Evidence map›Paper›PMID 30506405›Full record

ArticleChemistry Central journal2018

Synthesis and biological profile of substituted benzimidazoles.

Neelam Vashist, Surinder Singh Sambi, Balasubramanian Narasimhan, Sanjiv Kumar, Siong Meng Lim, Syed Adnan Ali Shah, Kalavathy Ramasamy, Vasudevan Mani

Abstract read
In one paragraph

Article in Chemistry Central journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Synthesis,RSC medicinal chemistry · 2025
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Neelam VashistSGT College of Pharmacy, Shree Guru Gobind Singh Tricentenary (SGT) University, Gurugram, 122505, India.
Surinder Singh SambiUniversity School of Chemical Technology, Guru Gobind Singh Indraprastha University, Sector-16C, Dwarka, New Delhi, 110078, India.
Balasubramanian NarasimhanFaculty of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, 124001, India. naru2000us@yahoo.com.ORCID http://orcid.org/0000-0002-9627-094X
Sanjiv KumarFaculty of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, 124001, India.
Siong Meng LimFaculty of Pharmacy, Universiti Teknologi MARA (UiTM), 42300, Bandar Puncak Alam, Selangor Darul Ehsan, Malaysia.
Syed Adnan Ali ShahFaculty of Pharmacy, Universiti Teknologi MARA (UiTM), 42300, Bandar Puncak Alam, Selangor Darul Ehsan, Malaysia.
Kalavathy RamasamyFaculty of Pharmacy, Universiti Teknologi MARA (UiTM), 42300, Bandar Puncak Alam, Selangor Darul Ehsan, Malaysia.
Vasudevan ManiDepartment of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraidah, 51452, Kingdom of Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA series of benzimidazole derivatives was developed and its chemical scaffolds were authenticated by NMR, IR, elemental analyses and physicochemical properties. The synthesized compounds were screened for their antimicrobial and antiproliferative activities. RESULTS AND DISCUSSION: The synthesized benzimidazole compounds were evaluated for their antimicrobial activity using the tube dilution method and were found to exhibit good antimicrobial potential against selected Gram negative and positive bacterial and fungal species. The compounds were also assessed for their anticancer activity exhibited using the SRB assay and were found to elicit antiproliferative activity against MCF7 breast cancer cell line, which was comparable to the standard drug.

conclusionAntimicrobial screening results indicated that compounds 1, 2 and 19 to be promising antimicrobial agents against selected microbial species and comparable to standard drugs which included norfloxacin and fluconazole. The anticancer screening results revealed that compounds, 12, 21, 22 and 29 to show the highest activity against MCF7 and their IC

Indexed as

Anticancer activityAntimicrobial activityBenzimidazolesSynthesis

Identifiers

PMID30506405
PMCPMC6768139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.